Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells

Hamid R. Djalilian, Yasuhiro Tsuboi, Masashi Ozeki, Muhammet Tekin, Ali R. Djalilian, Wesley Obritch, Jizhen Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hypothesis: To investigate the feasibility of gene therapy of the middle ear mucosa using a novel vector. Background: Given present medications are unable to affect chronic otitis media, cholesteatoma, or tympanic membrane perforation, newer methods of treatment like gene therapy for these diseases must be explored. These genes can then be used to alter cytokines in the middle ear, slow or stop cholesteatoma growth, or improve tympanic membrane perforation healing. Feline immunodeficiency virus (FIV), a new lentiviral vector has been found to have greater than 90% efficiency in transfecting epithelial cells. Therefore, in vivo gene therapy of middle ear mucosa cells was attempted. Methods: Twenty microliter of 5×105 vectors per ml FIV carrying the gene for green fluorescence protein (GFP) was introduced into the middle ears of Sprague-Dawley rats via a bulla approach. Results: Expression of the GFP gene was observed in the middle ear mucosa cells at 1 week post-inoculation indicating transfection. Conclusion: Gene therapy of the middle ear is feasible with a FIV-based vector.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalAuris Nasus Larynx
Volume29
Issue number2
DOIs
StatePublished - Mar 26 2002

Fingerprint

Feline Immunodeficiency Virus
Middle Ear
Genetic Therapy
Mucous Membrane
Tympanic Membrane Perforation
Cholesteatoma
Fluorescence
Otitis Media
Blister
Genes
Transfection
Sprague Dawley Rats
Proteins
Epithelial Cells
Cytokines
Growth

Keywords

  • Feline
  • GFP gene
  • Mucosa cells

Cite this

Djalilian, H. R., Tsuboi, Y., Ozeki, M., Tekin, M., Djalilian, A. R., Obritch, W., & Lin, J. (2002). Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells. Auris Nasus Larynx, 29(2), 183-186. https://doi.org/10.1016/S0385-8146(01)00131-6

Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells. / Djalilian, Hamid R.; Tsuboi, Yasuhiro; Ozeki, Masashi; Tekin, Muhammet; Djalilian, Ali R.; Obritch, Wesley; Lin, Jizhen.

In: Auris Nasus Larynx, Vol. 29, No. 2, 26.03.2002, p. 183-186.

Research output: Contribution to journalArticle

Djalilian, HR, Tsuboi, Y, Ozeki, M, Tekin, M, Djalilian, AR, Obritch, W & Lin, J 2002, 'Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells', Auris Nasus Larynx, vol. 29, no. 2, pp. 183-186. https://doi.org/10.1016/S0385-8146(01)00131-6
Djalilian HR, Tsuboi Y, Ozeki M, Tekin M, Djalilian AR, Obritch W et al. Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells. Auris Nasus Larynx. 2002 Mar 26;29(2):183-186. https://doi.org/10.1016/S0385-8146(01)00131-6
Djalilian, Hamid R. ; Tsuboi, Yasuhiro ; Ozeki, Masashi ; Tekin, Muhammet ; Djalilian, Ali R. ; Obritch, Wesley ; Lin, Jizhen. / Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells. In: Auris Nasus Larynx. 2002 ; Vol. 29, No. 2. pp. 183-186.
@article{d230180551504abfa8e2c821f0bc9959,
title = "Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells",
abstract = "Hypothesis: To investigate the feasibility of gene therapy of the middle ear mucosa using a novel vector. Background: Given present medications are unable to affect chronic otitis media, cholesteatoma, or tympanic membrane perforation, newer methods of treatment like gene therapy for these diseases must be explored. These genes can then be used to alter cytokines in the middle ear, slow or stop cholesteatoma growth, or improve tympanic membrane perforation healing. Feline immunodeficiency virus (FIV), a new lentiviral vector has been found to have greater than 90{\%} efficiency in transfecting epithelial cells. Therefore, in vivo gene therapy of middle ear mucosa cells was attempted. Methods: Twenty microliter of 5×105 vectors per ml FIV carrying the gene for green fluorescence protein (GFP) was introduced into the middle ears of Sprague-Dawley rats via a bulla approach. Results: Expression of the GFP gene was observed in the middle ear mucosa cells at 1 week post-inoculation indicating transfection. Conclusion: Gene therapy of the middle ear is feasible with a FIV-based vector.",
keywords = "Feline, GFP gene, Mucosa cells",
author = "Djalilian, {Hamid R.} and Yasuhiro Tsuboi and Masashi Ozeki and Muhammet Tekin and Djalilian, {Ali R.} and Wesley Obritch and Jizhen Lin",
year = "2002",
month = "3",
day = "26",
doi = "10.1016/S0385-8146(01)00131-6",
language = "English (US)",
volume = "29",
pages = "183--186",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Feline immunodeficiency virus-mediated gene therapy of middle ear mucosa cells

AU - Djalilian, Hamid R.

AU - Tsuboi, Yasuhiro

AU - Ozeki, Masashi

AU - Tekin, Muhammet

AU - Djalilian, Ali R.

AU - Obritch, Wesley

AU - Lin, Jizhen

PY - 2002/3/26

Y1 - 2002/3/26

N2 - Hypothesis: To investigate the feasibility of gene therapy of the middle ear mucosa using a novel vector. Background: Given present medications are unable to affect chronic otitis media, cholesteatoma, or tympanic membrane perforation, newer methods of treatment like gene therapy for these diseases must be explored. These genes can then be used to alter cytokines in the middle ear, slow or stop cholesteatoma growth, or improve tympanic membrane perforation healing. Feline immunodeficiency virus (FIV), a new lentiviral vector has been found to have greater than 90% efficiency in transfecting epithelial cells. Therefore, in vivo gene therapy of middle ear mucosa cells was attempted. Methods: Twenty microliter of 5×105 vectors per ml FIV carrying the gene for green fluorescence protein (GFP) was introduced into the middle ears of Sprague-Dawley rats via a bulla approach. Results: Expression of the GFP gene was observed in the middle ear mucosa cells at 1 week post-inoculation indicating transfection. Conclusion: Gene therapy of the middle ear is feasible with a FIV-based vector.

AB - Hypothesis: To investigate the feasibility of gene therapy of the middle ear mucosa using a novel vector. Background: Given present medications are unable to affect chronic otitis media, cholesteatoma, or tympanic membrane perforation, newer methods of treatment like gene therapy for these diseases must be explored. These genes can then be used to alter cytokines in the middle ear, slow or stop cholesteatoma growth, or improve tympanic membrane perforation healing. Feline immunodeficiency virus (FIV), a new lentiviral vector has been found to have greater than 90% efficiency in transfecting epithelial cells. Therefore, in vivo gene therapy of middle ear mucosa cells was attempted. Methods: Twenty microliter of 5×105 vectors per ml FIV carrying the gene for green fluorescence protein (GFP) was introduced into the middle ears of Sprague-Dawley rats via a bulla approach. Results: Expression of the GFP gene was observed in the middle ear mucosa cells at 1 week post-inoculation indicating transfection. Conclusion: Gene therapy of the middle ear is feasible with a FIV-based vector.

KW - Feline

KW - GFP gene

KW - Mucosa cells

UR - http://www.scopus.com/inward/record.url?scp=0036126072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036126072&partnerID=8YFLogxK

U2 - 10.1016/S0385-8146(01)00131-6

DO - 10.1016/S0385-8146(01)00131-6

M3 - Article

VL - 29

SP - 183

EP - 186

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 2

ER -